Key result
Cardiac contractility modulation therapy in HFrEF patients was associated with decreased HF-related hospitalization rate (p<0.0001) and increased left ventricular ejection fraction (p<0.0001).
Why the study?
The clinical course and cardiac reverse remodeling in patients with HFrEF receiving cardiac contractility modulation therapy needed to be assessed.
Does cardiac contractility modulation therapy improve clinical outcomes and cardiac reverse remodeling in patients with HFrEF?
Comparison
CCM therapy compared by lead number, baseline LVEF, and HF etiology
Design
Cohort study
Follow-up
24 months
Authors
Loading...
May support CCM-associated remodeling in HFrEF; leaves open efficacy confirmation in RCTs.
Cohort (n=55)
Does cardiac contractility modulation therapy improve clinical outcomes and cardiac reverse remodeling in patients with HFrEF?
In patients with HFrEF and narrow QRS, cardiac contractility modulation therapy is associated with improved clinical status, reduced hospitalizations, and positive cardiac reverse remodeling over 24 months.
Вандер et al. (2021) conducted a cohort in Heart failure with reduced ejection fraction (HFrEF) (n=55). Cardiac contractility modulation (CCM) therapy was evaluated on Hospitalizations and mortality due to decompensated HF, and changes in HF class, NTproBNP, peak oxygen consumption, and LVEF. Cardiac contractility modulation therapy in HFrEF patients was associated with decreased HF-related hospitalization rate (p<0.0001) and increased left ventricular ejection fraction (p<0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: